Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.IntelGenx Corp (IntelGenx) has reported that the US Patent and Trademark Office (USPTO) issued patent number 7,674,479 for a key patent application protecting its CPI-300, a high strength formulation of bupropion hydrochloride (HCl), the active ingredient in Wellbutrin XL.
Subscribe to our email newsletter
The patent entitled ‘Sustained-Release Bupropion and Bupropion/Mecamylamine Tablets’ discloses the formulation of pharmaceutical tablets containing sustained-release granules of Bupropion HCl distributed in a sustained-release matrix. The patent will provide broad protection for CPI-300 until 2027 (twenty years from the filing date) and upon regulatory approval be listed in the FDA Orange Book.
IntelGenx has recently received a complete response letter from FDA for its new drug application (NDA) for CPI-300, and is in the process of preparing an amendment to address the issues raised in the complete response letter.
Reportedly, IntelGenx and Cary Pharmaceuticals have entered into a collaborative agreement in November 2007 to jointly develop and commercialize CPI-300 using IntelGenx’s oral VersaTab delivery technology. Cary Pharmaceuticals serves as the NDA applicant for CPI-300.
Horst Zerbe, president and chief executive officer of IntelGenx, said: “The successful issuance of this patent provides formidable intellectual property protection for CPI-300 and further strengthens our competitive position in the substantial Bupropion market.”